Search Results - "Grafals‐Ruiz, Nilmary"

Toll Like Receptor 4 Inhibition Improves Antitumor Responses to MBQ‐167 in Triple Negative Breast Cancer Cells in vitro by Grafals‐Ruiz, Nilmary, Torres‐Sánchez, Anamaris, Romero‐Vega, Angélica C.

“…Triple negative breast cancer (TNBC) is an aggressive variant of breast cancer that lacks the expression of estrogen, progesterone, and human epithelial growth…”
Get full text

RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials by Lozada-Delgado, Eunice L., Grafals-Ruiz, Nilmary, Vivas-Mejía, Pablo E.

“…Glioblastoma multiforme (GBM) is the most common and deadliest type of primary brain tumor with a prognosis of 14months after diagnosis. Current treatment for…”
Get full text

Brain Targeted Gold Liposomes Improve RNAi Delivery for Glioblastoma by Grafals-Ruiz, Nilmary, Rios-Vicil, Christian I, Lozada-Delgado, Eunice L, Quiñones-Díaz, Blanca I, Noriega-Rivera, Ricardo A, Martínez-Zayas, Gabriel, Santana-Rivera, Yasmarie, Santiago-Sánchez, Ginette S, Valiyeva, Fatma, Vivas-Mejía, Pablo E

“…Glioblastoma (GBM) is the most common and lethal of the central nervous system (CNS) malignancies. The initiation, progression, and infiltration ability of…”
Get full text

Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer by Borrero-García, Luis D, Del Mar Maldonado, Maria, Medina-Velázquez, Julia, Troche-Torres, Angel L, Velazquez, Luis, Grafals-Ruiz, Nilmary, Dharmawardhane, Suranganie

“…Even though targeted therapies are available for cancers expressing oncogenic epidermal growth receptor (EGFR) and (or) human EGFR2 (HER2), acquired or…”
Get full text

MicroRNA-92b targets tumor suppressor gene FBXW7 in glioblastoma by Grafals-Ruiz, Nilmary, Sánchez-Álvarez, Annelis O, Santana-Rivera, Yasmarie, Lozada-Delgado, Eunice L, Rabelo-Fernandez, Robert J, Rios-Vicil, Christian I, Valiyeva, Fatima, Vivas-Mejia, Pablo E

“…Glioblastoma (GBM) is a highly aggressive and lethal primary brain tumor. Despite limited treatment options, the overall survival of GBM patients has shown…”
Get full text

Efficacy and delivery strategies of the dual Rac/Cdc42 inhibitor MBQ-167 in HER2 overexpressing breast cancer by Velázquez-Vega, Luis E., Rivera-Robles, Michael, Sánchez-Álvarez, Annelis O., Vivas-Mejía, Pablo E., Aponte-Reyes, Miciely, Cruz-Collazo, Ailed M., Grafals-Ruiz, Nilmary, Dorta-Estremera, Stephanie, Hernández-O'Farrill, Eliud, Vlaar, Cornelis P, Dharmawardhane, Suranganie

“…•The results presented herein demonstrate that free and liposomal MBQ-167 reduces cell viability, inhibit tumor growth, and decreases metastasis to lungs and…”
Get full text

Synthesis of Novel Heterocyclic Ferrocenyl Chalcones and Their Biological Evaluation by Alsina-Sánchez, Ámbar M., Montalvo-Vázquez, Sebastián, Grafals-Ruiz, Nilmary, Acosta, Carmen, Ormé, Emily M., Rodríguez, Israel, Delgado-Rivera, Sara M., Tinoco, Arthur D., Dharmawardhane, Suranganie, Montes-González, Ingrid C.

“…Breast cancer is currently the most commonly diagnosed cancer, with 287,850 new cases estimated for 2022 as reported by the American Cancer Society. Therefore,…”
Get full text

Reduced expression of enolase-1 correlates with high intracellular glucose levels and increased senescence in cisplatin-resistant ovarian cancer cells by Santana-Rivera, Yasmarie, Rabelo-Fernández, Robert J, Quiñones-Díaz, Blanca I, Grafals-Ruíz, Nilmary, Santiago-Sánchez, Ginette, Lozada-Delgado, Eunice L, Echevarría-Vargas, Ileabett M, Apiz, Juan, Soto, Daniel, Rosado, Andrea, Meléndez, Loyda, Valiyeva, Fatima, Vivas-Mejía, Pablo E

Get full text

Reduced expression of enolase-1 correlates with high intracellular glucose levels and increased senescence in cisplatin-resistant ovarian cancer cells by Santana-Rivera, Yasmarie, Rabelo-Fernández, Robert J, Quiñones-Díaz, Blanca I, Grafals-Ruíz, Nilmary, Santiago-Sánchez, Ginette, Lozada-Delgado, Eunice L, Echevarría-Vargas, Ileabett M, Apiz, Juan, Soto, Daniel, Rosado, Andrea, Meléndez, Loyda, Valiyeva, Fatima, Vivas-Mejía, Pablo E

“…Despite good responses to first-line treatment with platinum-based combination chemotherapy, most ovarian cancer patients will relapse and eventually develop a…”
Get full text

Delivery of Interference RNA Molecules to Ovarian Cancer Cells Using Gold‐Liposome Nanoparticle Conjugates by Quiñones‐Díaz, Blanca I., Grafals‐Ruiz, Nilmary, Barletta‐Bonanno, Gabriel L., Vivas‐Mejía, Pablo E.

“…RNA interference is a therapeutic modality in which RNA molecules, such as small interference RNAs (siRNAs) and microRNAs (miRNAs) (inhibitors and mimics), are…”
Get full text

MicroRNA‐92b is a potential therapeutic target for Glioblastoma treatment by Grafals‐Ruiz, Nilmary, Lozada‐Delgado, Eunice, Santana‐Rivera, Yasmarie, Rivera‐Diaz, Monica, Valiyeva, Fatma, Vivas‐Mejía, Pablo

“…Glioblastoma is the most aggressive type of primary brain tumor with an overall survival of 14.6 months with standard care treatment (surgery, radiotherapy,…”
Get full text

Abstract 1586: The potential therapeutic effect of the Rac/Cdc42 inhibitor MBQ-167 in glioblastoma in vitro by Almedina, Derealise Garcia, Grafals-Ruiz, Nilmary, Dharmawardhane, Suranganie, Torres-Sanchez, Anamaris

“…Glioblastoma is a highly aggressive astrocytoma known to form the most lethal type of primary brain tumor. Therapeutic options are limited because 94% of…”
Get full text

Abstract P2-01-05: MBQ-167 chemosensitizes triple-negative breast cancer cells to current chemotherapies and reduces paclitaxel-induced metastasis by Grafals-Ruiz, Nilmary, Cruz-Collazo, Ailed M., Torres-Sánchez, Anamaris, Dharmawardhane, Surangani

“…Triple-negative breast cancer (TNBC) is an aggressive and recurrent type of breast cancer that accounts for over 15% of new diagnoses yearly. Patients with…”
Get full text

Abstract 4714: Mechanisms by which the Rac & Cdc42 inhibitor MBQ-167 overcomes the adverse effects of paclitaxel in TNBC by Grafals-Ruiz, Nilmary, Sánchez-Orive, Patricia, Torres-Sánchez, Anamaris, Cruz-Collazo, Ailed, García-Almedina, Derealise, Dorta-Estremera, Stephanie, Dharmawardhane, Suranganie

“…Triple-negative breast cancer (TNBC) is the most aggressive, recurrent, and metastatic type of BC. Since there are limited targeted therapies available, the…”
Get full text

Abstract 2538: MiR-92b targets FBXW7 in GBM cells by Sanchez-Alvarez, Annelis Odette, Grafals-Ruiz, Nilmary, Santana-Rivera, Yasmarie, Valiyeva, Fatma, Rosado-Rivera, Nathaly M., Vivas-Mejía, Pablo E.

“…MicroRNA (miRNA) dysregulation plays a central role in the initiation, progression, and drug resistance of virtually all cancer types. MiRNA-based therapies…”
Get full text

Targeting MicroRNA-143 Leads to Inhibition of Glioblastoma Tumor Progression by Lozada-Delgado, Eunice L, Grafals-Ruiz, Nilmary, Miranda-Román, Miguel A, Santana-Rivera, Yasmarie, Valiyeva, Fatma, Rivera-Díaz, Mónica, Marcos-Martínez, María J, Vivas-Mejía, Pablo E

“…Glioblastoma (GBM) is the most common and aggressive of all brain tumors, with a median survival of only 14 months after initial diagnosis. Novel therapeutic…”
Get full text

Targeting microRNAs in Brain Tumors with Oligonucleotide-nanoparticle Conjugates by Grafals-Ruiz, Nilmary

“…Glioblastoma (GBM) is the most common and lethal malignancy of the central nervous system (CNS). The overall survival of GBM patients is 15 months with a…”
Get full text

Erratum: Reduced expression of enolase-1 correlates with high intracellular glucose levels and increased senescence in cisplatin-resistant ovarian cancer cells by Santana-Rivera, Yasmarie, Rabelo-Fernández, Robert J, Quiñones-Díaz, Blanca I, Grafals-Ruíz, Nilmary, Santiago-Sánchez, Ginette, Lozada-Delgado, Eunice L, Echevarría-Vargas, Ileabett M, Apiz, Juan, Soto, Daniel, Rosado, Andrea, Meléndez, Loyda, Valiyeva, Fatima, Vivas-Mejía, Pablo E

“…[This corrects the article on p. 1275 in vol. 12, PMID: 32355541.]…”
Get full text